Stroke, Acute Ischemic Clinical Trial
Official title:
Immediate Angioplasty For Acute Ischemic Stroke With Severe Intracranial Atherosclerotic Stenosis (MAGIC): A Multicenter, Prospective, Open-label, Blinded Endpoint, Randomized Controlled Trial
A multicenter, prospective, open-label, blinded endpoint, randomized controlled trial that aims to evaluate the effect of immediate angioplasty (with or without stenting) for acute ischemic stroke (AIS) with severe intracranial atherosclerotic stenosis (ICAS) in improving the 90-day functional outcome.
This study is a multicenter, prospective, open-label, blinded endpoint, randomized controlled trial designed to evaluate the effect of immediate angioplasty (with or without stenting) for AIS with severe ICAS. The primary outcome is the proportion of patients with a 90-day modified Rankin scale (mRS) of 0-2. Study intervention: (1) Participants in the experimental group will undergo immediate angioplasty (with or without stenting), and will receive the best medical treatment (BMM) after the procedure. (2) Participants in the control group will receive BMM alone. This study is anticipated to enroll 418 participants, with 209 participants in each group (1:1 ratio). ;